
|Videos|January 30, 2023
Overview of Triple Class Refractory Multiple Myeloma
Author(s)Joshua Richter, MD, Srdan Verstovsek, MD, PhD
Dr Joshua Richter explains triple class refractory myeloma and the need for more data on treatment options.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5










































